Gritstone bio, Inc. Stock Price, News & Analysis

Gritstone bio (GRTS) presented 6-month follow-up data from its Phase 1 CORAL-CEPI and CORAL-BOOST studies on self-amplifying mRNA (samRNA) vaccine candidates against SARS-CoV-2 at the ECCMID 2023. The results indicate that the samRNA vaccine effectively induces robust neutralizing antibody (nAb) responses that persist for at least 6 months in both vaccine-naïve and previously vaccinated individuals. Key highlights include strong nAb levels with the GRT-R914 and GRT-R910 candidates across diverse populations, including older adults. Both vaccines demonstrated favorable tolerability and the potential for long-term immunity against variants. The findings support the hypothesis that samRNA may serve as a next-generation vaccine platform.

Gritstone bio presented key findings at the 2023 AACR Annual Meeting in Orlando, focusing on its neoantigen vaccine programs, including the GRANITE trial for microsatellite-stable colorectal cancer (MSS-CRC) now in Phase 2/3. The study demonstrated vaccine-elicited T cell responses that may convert 'cold' tumors into 'hot' ones, enhancing treatment efficacy. Gritstone's EDGE™ platform, which predicts neoantigens, showed advancements in identifying class II HLA-presented neoantigens to boost CD4+ T cell responses. Notably, a KRAS G12C epitope was linked to positive clinical benefits. The company anticipates preliminary data from GRANITE by Q4 2023, showcasing the potential of personalized immunotherapies.

Gritstone bio, Inc. (Nasdaq: GRTS) has granted nonqualified stock options to a new employee for 20,000 shares at an exercise price of $2.76, equating to the stock's closing price on April 3, 2023. This grant is in compliance with Nasdaq Listing Rule 5635(c)(4) and is an inducement material to hiring the new employee. The options will vest over four years, with 25% vesting on the first anniversary of employment and the remainder vesting monthly, contingent on continued employment. Gritstone bio is focused on developing potent vaccines to advance treatments for viral diseases and solid tumors, leveraging innovative technology to improve patient outcomes.

Gritstone bio, Inc. (Nasdaq: GRTS) announced presentations at the 33rd ECCMID 2023 in Copenhagen, showcasing their self-amplifying mRNA (samRNA) vaccine candidates. The presentations will detail the CORAL program's efforts in fighting COVID-19, particularly with candidates targeting the virus's Spike protein. Key sessions include a poster presentation on samRNA vaccines in HIV-positive and healthy adults and an ePoster session on the GRT-R910 vaccine's immunogenicity in older volunteers. These studies aim to validate Gritstone’s innovative approach to infectious diseases.

Gritstone bio, Inc. (GRTS) announced multiple presentations at the 2023 AACR Annual Meeting, highlighting its innovative neoantigen vaccine programs. Key presentations include a poster on peptide-HLA interactions and a minisymposium discussing disease monitoring through genomics. The company detailed its proprietary EDGE™ neoantigen prediction capabilities and the progress of its GRANITE program, which is in a Phase 2/3 study for colorectal cancer. Gritstone emphasizes its commitment to developing potent vaccines targeting critical diseases, leveraging advanced technologies.